Elzbieta Dudek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elzbieta Dudek has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Marek Michalak
University of Alberta
3 shared publications- Alison Robinson
Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
1 shared publication - Allison Kraus
Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Amber M. Paul
Universities Space Research Association, Columbia, MD 21046, USA
1 shared publication - Christopher Power
Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication - Douglas W. Zochodne
Neuroscience and Mental Health Institute and Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada
1 shared publication
Latest Publications
- Open Access
- 8 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (5)
Calnexin is necessary for T cell transmigration into the central nervous system
In multiple sclerosis (MS), a demyelinating inflammatory disease of the CNS, and its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells gain access to the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage. Here, we discovered that calnexin, an ER chaperone, is highly abundant in human brain endothelial cells of MS patients. Conversely, mice lacking calnexin exhibited resistance to EAE induction, no evidence of immune cell infiltration into the CNS, and no induction of inflammation markers within the CNS. Furthermore, calnexin deficiency in mice did not alter the development or function of the immune system. Instead, the loss of calnexin led to a defect in brain endothelial cell function that resulted in reduced T cell trafficking across the blood-brain barrier. These findings identify calnexin in brain endothelial cells as a potentially novel target for developing strategies aimed at managing or preventing the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath in MS.
- 8 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (5)
Open AccessCalnexin is necessary for T cell transmigration into the central nervous system
In multiple sclerosis (MS), a demyelinating inflammatory disease of the CNS, and its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells gain access to the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage. Here, we discovered that calnexin, an ER chaperone, is highly abundant in human brain endothelial cells of MS patients. Conversely, mice lacking calnexin exhibited resistance to EAE induction, no evidence of immune cell infiltration into the CNS, and no induction of inflammation markers within the CNS. Furthermore, calnexin deficiency in mice did not alter the development or function of the immune system. Instead, the loss of calnexin led to a defect in brain endothelial cell function that resulted in reduced T cell trafficking across the blood-brain barrier. These findings identify calnexin in brain endothelial cells as a potentially novel target for developing strategies aimed at managing or preventing the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath in MS.